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Abstract
Purpose: Identifying among nephroblastoma those with a high propensity for distant metastases using cell cycle markers:
cyclin E as a regulator of progression through the cell cycle and Ki-67 as a tumor proliferation marker, since both are often
deregulated in many human malignancies.
Methodology/Principal Findings: A staining index (SI) was obtained by immunohistochemistry using anti-cyclin E and anti-
Ki-67 antibodies in paraffin sections of 54 postchemotherapy nephroblastoma including 42 nephroblastoma without
metastasis and 12 with metastases. Median cyclin E and Ki-67 SI were 46% and 33% in blastemal cells, 30% and 10% in
stromal cells, 37% and 29.5% in epithelial cells. The highest values were found for anaplastic nephroblastoma. A correlation
between cyclin E and Ki-67 SI was found for the blastemal component and for the epithelial component. Univariate analysis
showed prognostic significance for metastases with cyclin E SI in stromal cells, epithelial cells and blastemal cells (p=0.03,
p=0.01 and p=0.002, respectively) as well as with Ki-67 SI in blastema (p,10
24). The most striking data were that both
cyclin E SI and blastemal Ki-67 SI discriminated between patients with metastases and patients without metastasis among
intermediate-risk nephroblastoma.
Conclusions: Our findings show that a high cyclin E SI in all components of nephroblastoma is correlated with tumor
aggressiveness and metastases, and that assessment of its expression may have prognostic value in the categorization of
nephroblastoma.
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Introduction
Nephroblastoma is the most common pediatric tumor of the
kidney [1]. It arises from metanephric blastemal cells and
recapitulates renal embryogenesis. In Europe, patients are treated
according to the International Society of Pediatric Oncology
(SIOP) protocol, which consists of preoperative chemotherapy and
surgical resection followed by postoperative treatment [2]. This
latter step is adjusted on the basis of tumor histology and local
tumor stage. Stage I low-risk nephroblastoma receive no
postoperative treatment while high-risk tumors (i.e. diffuse
anaplasia and blastemal types) are treated with aggressive
chemotherapy. In the intermediate-risk tumor group (i.e. epithe-
lial, stromal, mixed, regressive and focal anaplasia types), over
90% of the patients are cured with the SIOP therapeutic strategy,
but a small fraction of children will relapse or metastasize. Thus,
there is still a need for accurate molecular prognostic markers to
identify these intermediate-risk tumors that need more intensive
treatment.
A vast amount of prognostic markers in nephroblastoma have
been reviewed [3,4] and no biological marker was found that
provided consistent predictive information regarding the clinical
outcome. Tumor-specific loss of heterozygosity (LOH) for
chromosomes 1p or 16q has been shown recently to be associated
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entered in NWTS-5 (National Wilms’ Tumor Study 5) [5] and is
the only biological marker with immediate implications for
treatment in the current Children’s Oncology Group (COG)
study. However, the prognostic value of these LOH for patients
treated with preoperative chemotherapy according to the
European SIOP protocol remains to be evaluated.
Some markers, such as Ki-67, may be relevant for assessing
proliferative activity [3]. Ki-67, a nuclear antigen associated with
cell proliferation, is present throughout the cell cycle and absent in
resting cells [6]. High Ki-67 is associated with a more aggressive
clinical behavior, and is found to be a significant determinant of
distant metastasis and tumor-related death in adult tumors [7].
Cyclin E is the regulatory subunit of the cyclin E–Cdk2
complex, which takes part in the control of progression through
G1 phase. Its activity is tightly regulated during normal cell cycle.
In neoplastic cells, deregulation is often observed and is thought to
play a fundamental role in tumorigenesis [8]. Cyclin E
overexpression has been studied and identified as an adverse
prognostic marker in a wide variety of human adult cancers
[9,10,11,12]. However, to our knowledge, cyclin E levels have
never been investigated in solid embryonal tumors, characterized
by a high proliferation rate.
The aim of our study was to evaluate cyclin E expression in
nephroblastoma using immunohistochemistry. To check if cyclin E
overexpression reflects only increased proliferation, levels of the
commonly used proliferation marker, Ki-67, were simultaneously
assessed. Analysis of the results was carried out taking into account
the global SIOP histology.
Results
Ki-67 and cyclin E expression in postchemotherapy
nephroblastoma
We determined Ki-67 and cyclin E staining index (SI) in all
histological components when present (Table 1). The median SI
for Ki-67 and cyclin E were 33% and 46% respectively in
blastemal cells, 10% and 30% in stromal cells, 29.5% and 37% in
epithelial cells (Figure 1).
In normal kidney parenchyma adjacent to the tumor, only
scattered Ki-67 positive nuclei were present in the renal tubules,
whereas we did not observe positive cyclin E nuclear staining
(Figure 2A–C).
Ki-67 and cyclin E SI were then analyzed according to the
histological type. Median SI are shown in Table 1 and are
illustrated in Figures 2 and 3:
In anaplastic nephroblastoma, the median SI in the blastemal
component (Fig. 2D) was 70% for Ki-67 (range, 42%–78%)
(Fig. 2E) and 94.5% for cyclin E (range, 75%–98%) (Fig. 2F). In
the stromal cells (Fig. 2G), it was 24% for Ki-67 (range, 12%–25%)
(Fig. 2H) and 37% for cyclin E (range, 30%–95%) (Fig. 2I). In the
epithelial cells (Fig. 2J), it was 43% for Ki-67 (range, 26%–62%)
(Fig. 2K) and 84.5% for cyclin E (range, 63%–97%) (Fig. 2L).
In blastemal type nephroblastoma (Fig. 3A), the median Ki-67
and cyclin E blastemal SI were 25.5% (range, 11%–40%) and 36%
(range, 5%–90%) respectively (Fig. 3B–C). To see if chemotherapy
influences Ki-67 or cyclin E expression, we analyzed five primary
nephrectomy cases: the median SI was 49% for Ki-67 (range, 31%–
80%) and 30% for cyclin E (range, 22%–92%) (data not shown).
In mixed type nephroblastoma (Fig. 3D), Ki-67 and cyclin E SI
were assessed in the blastemal component in 23 cases and in the
epithelial and stromal components in 19 cases. The median Ki-67
and cyclin E SI (Fig. 3E) were respectively 33% (range, 3%–91%)
and 60% (range, 6%–95%) (Fig. 3F) in the blastemal component,
10% (range, 1%–33%) and 26% (range, 5%–70%) in the stromal
component, 34% (range, 1%–72%) and 33.5% (range, 8%–75%)
in the epithelial component.
In stromal type nephroblastoma (Fig. 3G), the median SI was
5% for Ki-67 (range, 1.5%–20%) (Fig. 3H) and 30.5% for cyclin E
(range, 10%–69%) (Fig. 3I) in the stromal cells, 28% for Ki-67
(range, 8%–35%) and 30% for cyclin E (range, 25%–35%) in the
blastemal component, 12% for Ki-67 (range, 8%–40%) and
40.5% for cyclin E (range, 20%–80%) in the epithelial cells.
In the two epithelial type nephroblastoma (Fig. 3J), Ki-67 SI
were 29% and 32% (Fig. 3K). Cyclin E SI were 21% and 38%
(Fig. 3L).
We observed no significant difference for Ki-67 and cyclin E
blastemal SI in blastemal type nephroblastoma versus mixed type
(p=0.24 for Ki-67 and p=0.43 for cyclin E). We also did not
observe significant difference for Ki-67 and cyclin E stromal SI
between mixed and stromal type nephroblastoma (p=0.23 for Ki-
67 and p=0.61 for cyclin E).
Correlation between Ki-67 and cyclin E expression
A correlation between Ki-67 and cyclin E SI was observed in
blastemal (r=0.68, p,10
24) and epithelial (r=0.51, p=0.01)
components. In contrast, no correlation was observed for the
stromal component (r=0.15, p=0.44).
Correlation between Ki-67 and cyclin E expression and
metastases
Univariate analysis showed prognostic significance of blastemal
Ki-67 SI for metastases (p,10
24). Epithelial and stromal Ki-67 SI
did not have any prognostic value (p=0.29 and p=0.90
respectively). In contrast, cyclin E SI showed prognostic signifi-
cance for metastases in blastemal, stromal and epithelial cells
(p=0.002, p=0.03 and p=0.01 respectively). Multivariate analysis
could not be performed because of the low frequency of events.
Table 2 summarizes the main data in patients with and without
metastasis.
When we focused on intermediate-risk nephroblastoma, the
median blastemal Ki-67 SI was 61% (range, 60%–91%) for cases
with metastases (n=8) whereas it was 25% (range, 3%–69%) for
cases without metastasis (n=33). The median blastemal, stromal
and epithelial cyclin E SI were also higher in nephroblastoma with
metastases: 88% (range, 60%–95%), 55% (range, 29%–84%) and
51% (range, 47%–60%) respectively versus 34% (range, 6%–
90%), 24% (range, 5%–69%) and 30% (range, 8%–80%) in
nephroblastoma without metastasis. Figure 4 shows a representa-
tive pattern of Ki-67 and cyclin E SI in intermediate-risk mixed
type tumors with (Fig. 4A,C,E and G) or without metastasis
(Fig. 4B,D,F and H).
Using the Classification and Regression Trees (CART)
procedure, we developed cutoff scores to predict metastases
focusing on intermediate-risk nephroblastoma. We found a cutoff
of 40% for blastemal Ki-67 (sensitivity, 0.75; specificity, 0.85),
50% for blastemal cyclin E (sensitivity, 0.67; specificity, 0.79), 28%
for stromal cyclin E (sensitivity, 0.58; specificity, 0.79) and 44% for
epithelial cyclin E, (sensitivity, 0.5; specificity, 0.87).
Discussion
Our study showed that a high cyclin E SI in all components of
nephroblastoma was correlated with tumor aggressiveness and
metastases. The three histological components of nephroblastoma
(blastemal, epithelial and stromal) have different proliferating
potential. Furthermore, each component may have different
proliferating activity in each different histological type of
Cyclin E in Nephroblastoma
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2216Table 1. Ki-67 and cyclin E staining index (SI) in 54 postchemotherapy nephroblastoma. For each patient, age at surgery, sex,
clinical features, tumor local stage and subtype, metastases and follow-up were specified. Median SI are in bold.
Tumor
Age
(months) Sex Clinical features
Local
stage Type Metastases Outcome Ki-67 SI Cyclin E SI
blast strom epith blast strom epith
T308B 42 M Bilateral WT II diffuse
anaplasia
no alive 78 25 62 98 95 89
T187 48 F II diffuse
anaplasia
yes (stage IV) alive 42 12 26 96 37 80
T281 49 F II diffuse
anaplasia
yes (stage IV) alive 70 24 30
T220 78 F III diffuse
anaplasia
yes (stage IV+relapse) dead 55 57 75 97
T284 50 F III diffuse
anaplasia
yes (stage IV+relapse) dead 71 29 93 63
70 24 43 94.5 37 84.5
T207B 36 M Bilateral WT I blastemal no alive 15 20
T211 10 F I blastemal no alive 27 40
T248 69 F II blastemal no alive 36 90
T254 40 M II blastemal no alive 20 32
T257 29 F Hemihypertrophy I blastemal no alive 24 13
T263 163 F II blastemal no alive 11 70
T270B 12 F III blastemal no alive 36 5
T279 45 F II blastemal no alive 40 90
25.5 36
T96 16 M Beckwith Wiedemann I mixed no alive 12 3 24 10
T100 46 M II mixed no alive 10 72 48 60
T163 16 F Proteinuria II mixed no alive 32 21 65
T189 29 M II mixed no alive 25 12 30 20
T196 26 F II mixed no alive 20 90
T200 56 F Bilateral WT I mixed no alive 46 33 36 25 26 25
T204 21 M Denys-Drash/Bilateral
WT
II mixed no alive 17 20
T213A 35 F Perlman/Bilateral WT III mixed no alive 5 5 30 20 5 20
T231 38 F II mixed no alive 30 4 61 21
T246 14 F II mixed no alive 41 90
T255 13 M I mixed no alive 30 10 34 33 33 34
T261 35 M Beckwith Wiedemann II mixed no alive 12 20 11 75
T268 14 F Bilateral WT I mixed no alive 3 1 10 6 8 14
T271A 12 M Hypospadias/Bilateral
WT
II mixed no alive 33 6 43 44 26 33
T275 21 F I mixed no alive 40 48 60 60
T308A 17 M Bilateral WT II mixed no alive 23 10 15 33 5 30
T400 23 F III mixed no alive 17 2 46 25 23 22
T401 31 F III mixed no alive 45 11 34 35 30 30
T402 23 M III mixed no dead 69 20 41 80 61 72
T404 40 M II mixed no alive 23 11 20 8
T405 39 M Hemihypertrophy III mixed no alive 14 2 1 84 36 40
T406 82 F Hemihypertrophy III mixed no alive 40 2,3 13 87 24 36
T202 20 M Bilateral WT I mixed yes (relapse) alive 60 10 50 60 55 60
T212 18 M I mixed yes (relapse) alive 61 95
T310 17 M III mixed yes (relapse) alive 91 2 60 95 70 47
T218 38 M III mixed yes (stage IV+relapse) alive 60 82
T245 43 M I mixed yes (stage IV+relapse) alive 70 88
Cyclin E in Nephroblastoma
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Age
(months) Sex Clinical features
Local
stage Type Metastases Outcome Ki-67 SI Cyclin E SI
blast strom epith blast strom epith
33 10 34 60 26 33.5
T201 10 M II stromal no alive 20 40 60 80
T209 8 F II stromal no alive 11 23
T247 47 M I stromal no alive 2 12
T269 10 F I stromal no alive 4 69
T272 14 F II stromal no alive 8 2 8 25 32 20
T280 17 F WAGR I stromal no alive 35 6 12 35 10 30
T403 35 F I stromal no alive 28 5 12 NI NI NI
T234 36 M I stromal yes (stage IV) alive 1,5 47
T262 33 F Bilateral WT I stromal yes (relapse) dead 5 11 29 51
28 5 12 30 30.5 40.5
T219 11 F I epithelial no alive 32 38
T238 7 M I epithelial no alive 29 21
30,5 29,5
T94 56 F I regressive no alive 5 13
T264 70 F III regressive no alive 14 46
T216 73 M III regressive yes (stage IV) alive 12 84
9,5 29,5
blast=blastemal cells, strom=stromal cells, epith=epithelial cells, NI=noninterpretable
doi:10.1371/journal.pone.0002216.t001
Table 1. cont.
Figure 1. Box-Plot of the median Ki-67 and cyclin E SI in the different components of postchemotherapy nephroblastoma.
doi:10.1371/journal.pone.0002216.g001
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blastemal component of high-risk blastemal predominant nephro-
blastoma or to the blastemal component of an intermediate-risk
histological type. However, in this latter type, such blastemal
component can be aggressive too. This hypothesis is supported by
the fact that distant metastases can develop in cases of stage I
localized nephroblastoma, with intermediate-risk histology. Thus,
markers enabling identification of aggressive component are of
great interest.
Numerous studies have been reported which analyze the
expression of genes at the RNA or protein level in order to detect
correlations with adverse outcome [3,4,13,14,15,16,17]. Potential
markers included proliferation markers, apoptosis-associated mol-
ecules, growth factors and cell adhesion molecules. For some of
these molecules, i.e. the antiapoptotic factor Bcl-2 [18], TGFa [19],
the angiogenic growth factor VEGF and its receptor Flt-1 [20],
IGFIR (type I insulin-like growth factor receptor) [14], blastemal
staining was indicative of clinical progression but epithelial staining
has no prognostic value. To date, among the predictive markers
identified, no immunohistochemistry staining has proven to be
relevant in the three histological components of nephroblastoma.
It is well established that characterization of clinical relevant
prognostic markers will require studies of combination of markers.
However, difficulties in validating molecules previously reported
[4] highlight the fact that the first step that consists of identifying
single reliable markers, which could be further included in large
association studies, must go on.
In this study, we analyzed two cell-cycle markers, Ki-67 and
cyclin E, using immunohistochemistry in different components of
postchemotherapy nephroblastoma histologically classified accord-
ing to the SIOP classification. We determined Ki-67 SI in the
three components of nephroblastoma and found the highest values
in blastemal and epithelial components, as previously reported
[21]. The clinical value of proliferation markers such as Ki-67 in
nephroblastoma is still subject to debate. Nagoshi et al. [22] did
not find any relationship between proliferation rates and patient
survival whereas other studies [21,23] showed that blastemal Ki-
67 is a prognostic factor in pretreated nephroblastoma. Our study
demonstrates that Ki-67 SI in blastemal cells is a highly significant
indicator of metastases whereas it has no prognostic value in
epithelial nor in stromal cells. When focusing only on intermedi-
ate-risk nephroblastoma, we still found higher values of blastemal
Figure 2. Hematoxylin and eosin staining (H&E), Ki-67 and cyclin E immunostaining in normal kidney and diffuse anaplastic type
nephroblastoma. Normal kidney (A, H&E) shows only scattered positive nuclei in tubules after using Ki-67 antibody (B) and no positive nuclei after
using cyclin E antibody (C). Original magnification,640. Diffuse anaplastic nephroblastoma with anaplastic cells in the blastemal (D), stromal (G) and
epithelial (J) component (H&E; original magnification,640). Immunostaining shows numerous blastemal positive cells (E,F), stromal (H,I) and epithelial
cells (K,L) using Ki-67 (E,H,K) and cyclin E (F,I,L). Original magnification, 640 for E, H, I, K, L, 6100 for F.
doi:10.1371/journal.pone.0002216.g002
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those without metastasis.
Cyclin E, a G1-cyclin, is a marker of cell-cycle progression.
Overexpression ofcyclinE has beendemonstrated to beanindicator
of poor prognosis in many cancers [9,10,11,12]. In the cyclin E
promoter, several WT1 binding sites have been identified and WT1,
which is the tumor suppressor gene defective in some nephroblas-
toma, has a repressive effect on cyclin E expression [24]. But, to our
knowledge, cyclin E expression has never been studied in
nephroblastoma. Faussillon et al. reported overexpression of another
cyclin, cyclin D2 (CCND2), in 86% of Wilms’ tumor, supporting the
idea that alteration at the G1/S cell cycle control point is of
biological significance in nephroblastoma [25]. However they found
no association between relapse and cyclin D2 overexpression.
We used an antibody that can recognize both full-length and
lower molecular weight isoforms of cyclin E. The latter are of
particular interest because recent data demonstrate that they are
specific to tumor cells [26,27]. We found the highest values for cyclin
E SI in blastemal cells with prognostic significance for distant
metastases. Cyclin E is also largely expressed in epithelial and
stromal cells where it has a prognostic value too. Our study
demonstrates that increased cyclin E expression is associated with
distant metastases for whichever histological component of nephro-
blastoma it is assessed in. Moreover when focusing on intermediate-
risk nephroblastoma, the ones with metastases have higher cyclin E
SI in the three components than those without metastasis.
We observed a correlation between Ki-67 and cyclin E levels in
blastemal and epithelial components. These data suggest that high
cyclin E SI, at least in these two components, may reflect increased
proliferative activity. However, we found a decreased blastemal
proliferation, as assessed by Ki-67 after chemotherapy, in
accordance with another study [21] whereas no variation of
blastemal cyclin E SI was found, suggesting that cyclin E is not
only a proliferation marker. Some studies assessing Ki-67 and
cyclin E activities in breast cancer also concluded that cyclin E
provides additional information in that it represents a marker for
both proliferation and oncogenesis [28,29]. Porter et al. [28]
reported a subset of tumors with discordant cyclin E expression
and proliferation index (i.e., high cyclin E and low Ki-67 levels)
showing a strong association with mortality. Moreover, cyclin E
staining detects tumor cells committed to cell division (late G1 and
beyond). Such improvement in tumor phenotyping may enable
prediction of responsiveness to chemotherapy targeted at cells in S
and M phases [29]. Even if the basis for cyclin E prognostic
Figure 3. Hematoxylin and eosin staining, Ki-67 and Cyclin E immunostaining in nonanaplastic nephroblastoma. Examples of a
blastemal type nephroblastoma (A, H&E) with a median SI of 25,5% for Ki-67 (B) and of 36% for cyclin E (C), of a blastemal component of a mixed type
nephroblastoma (D, H&E) with a median SI of 33% for Ki-67 (E) and of 60% for cyclin E (F), of a stromal type nephroblastoma (G, H&E), with a median SI
of 5% for Ki-67 (H) and of 30,5% for cyclin E (I), of an epithelial type nephroblastoma (J, H&E), with a SI of 30% for Ki-67 (K) and for cyclin E (L). Original
magnification, 640 for all panels except C, I, L (6100).
doi:10.1371/journal.pone.0002216.g003
Cyclin E in Nephroblastoma
PLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2216significance is not known, a major hypothesis is that cyclin E
overexpression reflects alterations in any part of the p16–cyclinD–
Rb–E2F pathway, which is mutated in most cancers. Thus, cyclin
E expression may be a single convenient marker of alterations
occurring in a very complex pathway [8].
Using a CART procedure, we determined cyclin E and Ki-67
cutoff scores for metastasis prediction. A high specificity was found
for Ki-67 and cyclin E, but sensitivity was higher for blastemal Ki-
67 than for cyclin E. Optimal determination of these cutoffs needs
a larger cohort of patients and a centralized immunohistochemical
study to avoid technical variations.
As a summary, blastemal, epithelial and stromal cyclin E SI and
blastemal Ki-67 SI are significant determinants of distant
metastases. Accurate postoperative chemotherapy is based on
histology and staging. Risk histological stratification could also
include immunohistochemical analyses to better explore aggres-
siveness in the different components of nephroblastoma. Cooper-
ative larger studies focusing on intermediate-risk nephroblastoma
are needed to determine if these two markers should be considered
for stratification in future trials.
Materials and Methods
Patients
This retrospective study included 54 tumors removed from 53
patients (23 males and 30 females). Eight of these patients were
syndromic: one WAGR syndrome, one Denys–Drash syndrome,
one Perlman syndrome and five Beckwith–Wiedemann syndrome
or hemihypertrophy patients. The patients were seven to
163 months of age; the median age at surgery was 32 months.
All patients were treated by neoadjuvant chemotherapy before
nephrectomy. All the slides were reviewed by the French National
referent for SIOP-2001 Nephroblastoma Study (LBG) and local
pathologists. Exclusion criteria were: low-risk tumors and
regressive type nephroblastoma with more than 90% of chemo-
therapy-induced changes.
Thirteen high-risk nephroblastoma (5 anaplastic and 8 post-
chemotherapy blastemal types) and 41 intermediate-risk nephro-
blastoma (9 stromal, 3 regressive, 27 mixed and 2 epithelial types)
were studied. Pathological local staging was: stage I (n=20), stage
II (n=21), stage III (n=13). Three blastemal type and 2 mixed
type from primary nephrectomy cases (4 under seven months of
age and one with a highly cystic tumor) were also separately
analyzed for comparison.
Forty-six tumors were removed from patients with a localized
disease at diagnosis (i.e. unilateral or bilateral nephroblastoma,
without metastasis), and 8 tumors from patients with metastases at
diagnosis (clinical stage IV). Among the 46 patients with localized
disease, 4 developed metastases after nephrectomy. The median
follow-up was 57 months.
Specimen characteristics
This retrospective study was performed on samples obtained
from the SIOP-2001 nephroblastoma protocol and conducted
Table 2. Clinical, histological and immunohistochemical characteristics of patients with nephroblastoma with or without
metastasis.
Variables Patients with metastases (N=12) Patients without metastasis (N=42)
Age (months) 40.5* (17–78) 26* (7–163)
Male 7 (58%) 17 (40%)
Preoperative chemotherapy 12 (100%) 42 (100%)
Sub-type NB:
Anaplastic 4 (33%) 1 (2%)
Blastemal 0 (0%) 8 (19%)
Epithelial 0 (0%) 2 (5%)
Mixed 5 (42%) 22 (52%)
Regressive 1 (8%) 2 (5%)
Stromal 2 (17%) 7 (17%)
Pathological local staging:
I 5 (42%) 15 (36%)
II 2 (17%) 19 (45%)
III 5 (42%) 8 (19%)
Death 3 (25%) 1 (2%)
Blastemal cells (SI: median, range)
Ki-67 61 (42–91) 26 (3–78)
Cyclin E 90.5 (60–96) 35 (5–98)
Stromal cells (SI: median, range)
Ki-67 10 (1.5–24) 10 (1–33)
Cyclin E 47 (29–84) 25 (5–95)
Epithelial cells(SI: median, range)
Ki-67 39.5 (11–60) 29.5 (1–72)
Cyclin E 61.5 (47–97) 31.5 (8–89)
*significant difference between median age of patients with and without metastasis (p=0.04)
doi:10.1371/journal.pone.0002216.t002
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donors obtained for collection of this material. All nephrectomy
specimens were fixed in 10% buffered formalin. For each tumor,
at least two paraffin-embedded tissue sections, representative of
the global histology, were selected for immunohistochemical
analysis.
Antibodies
Primary antibodies were: mouse monoclonal anti-human Ki-67
antigen (clone MIB-1, DakoCytomation, Glostrup, Denmark) and
rabbit polyclonal affinity purified antibody against a peptide
mapping at the C-terminus of the human cyclin E (C-19, Santa
Cruz Biotechnology, Santa Cruz, CA).
Immunohistochemical staining
After paraffin removal, sections were heated in a water bath in
sodium citrate buffer 0.1 M, pH 6.0 for 40 min for antigen
retrieval. Endogenous peroxidase activity was quenched with a 3%
hydrogen peroxide solution. The slides were then incubated with
primary antibody: anti-MIB-1 (1:50) for 30 min at room
temperature or anti-cyclin E antibody (1:80) overnight at 4uC.
For MIB-1 primary antibody detection, incubation with biotiny-
lated sheep anti-mouse immunoglobulin for 30 min followed by
incubation with horseradish peroxidase coupled streptavidin for
30 min was performed. For anti-cyclin E primary antibody
detection, the DAKO EnVision system (DakoCytomation) was
used (30 min). In both cases, 3,39-diaminobenzidine was used as a
substrate. Sections were counterstained with hematoxylin.
Quantification of labeled cells
Immunostaining was assessed by two independent observers
blinded to clinical outcome and local staging. Staining was
evaluated in tumor cells and adjacent normal kidney. Only nuclear
staining was considered as positive. The intensity of staining
was not recorded. For anti-cyclin E antibody, the positive control
was a breast adenocarcinoma [28]. We recorded at high
magnification the number of cyclin E and Ki-67 positive nuclei
in at least 500 cells in representative fields. The average
percentage of stained tumor cells was calculated and assigned to
a staining index (SI).
Figure 4. Immunostaining in mixed type nephroblastoma with or without associated metastasis. Example of high Ki-67 (A) and high
cyclin E SI (C,E,G) in the blastemal (A,C), in the stromal (E) or epithelial (G) component of a patient with a stage I mixed type nephroblastoma and
pulmonary metastases (M+) in comparison with a patient with a stage III mixed type nephroblastoma without metastasis (M-) and low Ki-67 (B) and
cyclin E (D,F,H) SI in corresponding components.
doi:10.1371/journal.pone.0002216.g004
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Results are expressed as median and extreme values for
quantitative variables, and numbers (percentages) for qualitative
variables. Relationships between metastasis and age, Ki-67 SI,
cyclin E SI were studied by non-parametric Wilcoxon Rank Sum
test. Association between Ki-67 and cyclin E SI was studied by
Spearman correlation statistics.
We developed cutoff scores to predict metastasis with Ki-67 and
cyclin E in the different components of nephroblastoma by the
CART (Classification and Regression Trees) procedure [30]. All
tests were two tailed. Statistical analyses were performed using the
SAS 9.1 (SAS Inc, Cary, NC) software package, with p,0.05
considered as statistically significant.
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